SAN DIEGO, Sept. 6, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the publication of two abstracts that have been accepted for poster presentations at the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place both virtually and at the Paris Expo Porte de Versailles in Paris, France from September 9 – 13, 2022.
The full texts of the published abstracts can be found on the ESMO Congress 2022 website. Details on the corresponding posters are shown below.
Poster Title: | The PLK1 Inhibitor Onvansertib Overcomes Irinotecan Resistance in RAS-mutated (mRAS) Metastatic Colorectal Cancer (mCRC) In Vivo and in Patients |
Speaker: Poster Number: | Scott Kopetz, M.D., Ph.D. 366P |
Session Title: | Poster Session 7 |
Session Date: | September 11, 2022 |
Session Hours: | 9:00 AM – 5:00 PM CEST |
Location: | Poster Area, Hall 4 |
The abstract includes findings from an Expanded Access Program (EAP) in which patients with KRAS-mutated metastatic colorectal cancer (mCRC) who failed or progressed on standard-of-care, including irinotecan, were treated with onvansertib in combination with FOLFIRI/bevacizumab. These findings showed that early changes in KRAS mutant allelic frequency (MAF) were associated with increased benefit in the EAP. In addition, the abstract includes results from murine studies in patient-derived xenograft (PDX) models of RAS-mutated, irinotecan-resistant colorectal cancer. These data, together with findings from the EAP, suggest onvansertib can overcome irinotecan resistance in RAS-mutated colorectal cancer. Additional findings from the EAP and data from murine studies will be announced during the upcoming congress, in accordance with ESMO's embargo policies.
Poster Title: | Early Decreases in KRAS Mutant Allele Frequency (MAF) Predicts ClinicalBenefit to the PLK1 Inhibitor Onvansertib in Combination with FOLFIRI/bev in2L treatment of metastatic colorectal carcinoma (mCRC) |
Speaker: Poster Number: | Heinz-Josef Lenz, M.D. 397P |
Session Title: | Poster Session 8 |
Session Date: | September 11, 2022 |
Session Hours: | 9:00 AM – 5:00 PM CEST |
Location: | Poster Area, Hall 4 |
The abstract includes data from an ongoing Phase 1b/2 trial evaluating onvansertib in combination with FOLFIRI/bevacizumab in second-line KRAS-mutated mCRC. The data show that the subset of patients with ≥90% decreases in KRAS MAF in circulating tumor DNA after one cycle of treatment had a significantly greater objective response rate and significantly longer progression-free survival compared to the subset of patients with decreases in KRAS MAF